Barclays’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.97M | Hold |
10,000
| – | – | ﹤0.01% | 2361 |
|
|
2025
Q4 | $1.84M | Hold |
10,000
| – | – | ﹤0.01% | 2996 |
|
|
2025
Q3 | $1.53M | Hold |
10,000
| – | – | ﹤0.01% | 3075 |
|
|
2025
Q2 | $1.4M | Sell |
10,000
-8,500
| -46% | -$1.19M | ﹤0.01% | 3110 |
|
|
2025
Q1 | $2.72M | Sell |
18,500
-21,500
| -54% | -$3.11M | ﹤0.01% | 2397 |
|
|
2024
Q4 | $5.24M | Sell |
40,000
-200,450
| -83% | -$28.1M | ﹤0.01% | 2119 |
|
|
2024
Q3 | $37.5M | Buy |
+240,450
| New | +$38.8M | 0.01% | 786 |
|
|
2024
Q2 | – | Sell |
-45,450
| Closed | -$6.16M | – | 4870 |
|
|
2024
Q1 | $6.16M | Hold |
45,450
| – | – | ﹤0.01% | 1719 |
|
|
2023
Q4 | $6.12M | Buy |
+45,450
| New | +$5.91M | ﹤0.01% | 1920 |
|
|
2023
Q2 | – | Sell |
-70,750
| Closed | -$9.82M | – | 4558 |
|
|
2023
Q1 | $9.82M | Buy |
70,750
+30,000
| +74% | +$4.04M | ﹤0.01% | 1171 |
|
|
2022
Q4 | $5.53M | Buy |
+40,750
| New | +$5.11M | ﹤0.01% | 1550 |
|
|
2022
Q1 | – | Sell |
-750
| Closed | -$87K | – | 4945 |
|
|
2021
Q4 | $87K | Buy |
+750
| New | +$88.2K | ﹤0.01% | 3759 |
|
|
2021
Q1 | – | Sell |
-850
| Closed | -$85K | – | 4690 |
|
|
2020
Q4 | $85K | Hold |
850
| – | – | ﹤0.01% | 4202 |
|
|
2020
Q3 | $93K | Hold |
850
| – | – | ﹤0.01% | 4290 |
|
|
2020
Q2 | $90K | Sell |
850
-30,200
| -97% | -$3.12M | ﹤0.01% | 4586 |
|
|
2020
Q1 | $2.77M | Sell |
31,050
-44,050
| -59% | -$4.15M | ﹤0.01% | 1984 |
|
|
2019
Q4 | $7.49M | Buy |
75,100
+3,650
| +5% | +$344K | ﹤0.01% | 1619 |
|
|
2019
Q3 | $6.37M | Sell |
71,450
-254,200
| -78% | -$22M | ﹤0.01% | 1645 |
|
|
2019
Q2 | $26.9M | Buy |
325,650
+299,650
| +1,153% | +$23.5M | 0.02% | 771 |
|
|
2019
Q1 | $2.1M | Buy |
26,000
+2,250
| +9% | +$177K | ﹤0.01% | 2512 |
|
|
2018
Q4 | $1.8M | Buy |
23,750
+3,250
| +16% | +$254K | ﹤0.01% | 2506 |
|
|
2018
Q3 | $1.62M | Sell |
20,500
-61,500
| -75% | -$4.65M | ﹤0.01% | 3129 |
|
|
2018
Q2 | $5.76M | Buy |
82,000
+6,250
| +8% | +$450K | ﹤0.01% | 1612 |
|
|
2018
Q1 | $5.3M | Sell |
75,750
-121,150
| -62% | -$8.39M | ﹤0.01% | 1589 |
|
|
2017
Q4 | $13.7M | Buy |
196,900
+3,650
| +2% | +$246K | 0.01% | 1015 |
|
|
2017
Q3 | $13.1M | Sell |
193,250
-165,700
| -46% | -$10.5M | 0.01% | 890 |
|
|
2017
Q2 | $24.5M | Buy |
358,950
+72,850
| +25% | +$4.76M | 0.03% | 509 |
|
|
2017
Q1 | $17.8M | Sell |
286,100
-5,150
| -2% | -$300K | 0.02% | 604 |
|
|
2016
Q4 | $15.9M | Buy |
291,250
+231,450
| +387% | +$13.1M | 0.02% | 705 |
|
|
2016
Q3 | $3.93M | Buy |
59,800
+24,700
| +70% | +$1.61M | ﹤0.01% | 1478 |
|
|
2016
Q2 | $2.12M | Buy |
35,100
+16,350
| +87% | +$950K | ﹤0.01% | 1955 |
|
|
2016
Q1 | $1.05M | Sell |
18,750
-12,000
| -39% | -$721K | ﹤0.01% | 2473 |
|
|
2015
Q4 | $2.03M | Sell |
30,750
-11,600
| -27% | -$761K | ﹤0.01% | 2023 |
|
|
2015
Q3 | $2.63M | Sell |
42,350
-38,250
| -47% | -$2.52M | ﹤0.01% | 1897 |
|
|
2015
Q2 | $5.08M | Buy |
80,600
+52,500
| +187% | +$3.59M | 0.01% | 1472 |
|
|
2015
Q1 | $1.91M | Sell |
28,100
-1,500,700
| -98% | -$104M | ﹤0.01% | 2368 |
|
|
2014
Q4 | $107M | Sell |
1,528,800
-412,100
| -21% | -$29.5M | 0.1% | 158 |
|
|
2014
Q3 | $138M | Buy |
1,940,900
+556,100
| +40% | +$40.7M | 0.13% | 109 |
|
|
2014
Q2 | $102M | Buy |
1,384,800
+1,212,300
| +703% | +$87.6M | 0.11% | 140 |
|
|
2014
Q1 | $11M | Buy |
172,500
+127,100
| +280% | +$8.21M | 0.01% | 1073 |
|
|
2013
Q4 | $2.68M | Buy |
45,400
+18,500
| +69% | +$1M | ﹤0.01% | 2375 |
|
|
2013
Q3 | $1.37M | Buy |
26,900
+11,800
| +78% | +$593K | ﹤0.01% | 3001 |
|
|
2013
Q2 | $714K | Buy |
+15,100
| New | +$769K | ﹤0.01% | 3789 |
|
Other funds holding AZN
IA
VCM
VAM
Barclays's AZN Position: Q1 2026 in Review
Barclays increased its AstraZeneca (AZN) stake by 300% in Q1 2026, buying an estimated $794M and bringing the position to 5,491,992 shares worth $1.08B. The position accounts for 0.26% of the portfolio, ranked #54.
Barclays first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Barclays held 5,491,992 shares of AstraZeneca worth $1.08B as of Q1 2026.
- Barclays bought 4,119,190 AstraZeneca shares in Q1 2026, an estimated $794M.
- AstraZeneca made up 0.26% of Barclays's portfolio in Q1 2026, its #54 holding.
- Barclays first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.